The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 344 participants.

Also called NCT01106690

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 344 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01106690
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Finland, France, Germany, Greece, India, Mexico, Spain, Thailand, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01106690. Randomized; triple masking; primary purpose treatment. Start 2010-06 (registry gives no type); primary completion 2011-11 (actual). Results posted on 2013-05-21.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo
Intervention (Drug)
Canagliflozin
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Metformin
Intervention (Drug)
Pioglitazone
Lead sponsor
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01106690
Content hash
1ae47c835e784394d71256b9a95375ba88001edaed2752e160cd3fb034f9d431